Progress towards an HIV vaccine based on recombinant Bacillus Calmette–Guérin: failures and challenges

References

• Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science280(5371), 1871–1873 (1998).
   PubMed Web of Science ®Google Scholar
• Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol.68(7), 4650–4655 (1994).
   PubMed Web of Science ®Google Scholar
• Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science279(5359), 2103–2106 (1998).
   PubMed Web of Science ®Google Scholar
• Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med.181(4), 1365–1372 (1995).
   PubMed Web of Science ®Google Scholar
• Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest.102(9), 1758–1765 (1998).
   PubMed Web of Science ®Google Scholar
• Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant Vaccines. Nature351(6326), 456–460 (1991).
   PubMed Web of Science ®Google Scholar
• Melancon-Kaplan J, Hunter SW, McNeil M et al. Immunological significance of Mycobacterium leprae cell walls. Proc. Natl Acad. Sci. USA85(6), 1917–1921 (1988).
   PubMed Web of Science ®Google Scholar
• Oiso R, Fujiwara N, Yamagami H et al. Mycobacterial Trehalose 6, 6´- dimycolate preferentially induces type 1 helper T cell responses through signal transducer and activator of transcription 4 protein. Microb. Pathol.39(1–2) 35–43 (2005).
   PubMed Web of Science ®Google Scholar
• Fujita Y, Naka T, Doi T, Yano I. Direct molecular mass determination of trehalose monomycolate from 11 species of mycobacteria by MALDI-TOFF mass spectrometry. Microbiology151(Pt 5), 1443–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Libraty DH, Krutzik SR et al. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science285, 732–736 (1999).
   PubMed Web of Science ®Google Scholar
• Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun.71, 1672–1679 (2003).
   PubMed Web of Science ®Google Scholar
• Behr MA BCG-different strains, different vaccines? Lancet Infect. Dis.2(2) 86–92 (2002).
   PubMed Web of Science ®Google Scholar
• Dennehy M, Williamson AL Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine23, 1209–1224 (2005).
   PubMed Web of Science ®Google Scholar
• Lucas S, Nelson AM. Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In: Tuberculosis: Pathogenesis, Protection and Control. Bloom BR (Ed.). Washington, DC, USA, 503–513 (2002).
   Google Scholar
• Jacobs WR Jr, Tuckman M, Bloom BR. Introduction of foreign DNA into mycobacteria using a shuttle plasmid. Nature327(6122), 532–535 (1987).
   PubMed Web of Science ®Google Scholar
• Matsuo K, Yamaguchi R, Yamazaki A et al. Establishment of a foreign antigen secretion system in mycobacteria. Infect. Immun.58(12), 4049–4054 (1990).
   PubMed Web of Science ®Google Scholar
• Fuerst TR, Stover CK, de la Cruz VF. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine. Biotechnol. Ther.2(1–2), 159–178 (1991).
   PubMedGoogle Scholar
• Fuerst TR, de la Cruz VF, Bansal GP, Stover CK. Development and analysis of recombinant BCG vector systems. AIDS Res. Hum. Retroviruses.8(8), 1451–1455 (1992).
   PubMed Web of Science ®Google Scholar
• Dhar N, Rao V, Tyagi AK. Recombinant BCG approach for development of vaccines: cloning and expression of immunodominant antigens of M. tuberculosis. FEMS Microbiol Lett.190(2), 309–316 (2000).
   PubMed Web of Science ®Google Scholar
• Aldovini A, Young RA. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature351(6326), 479–482 (1991).
   PubMed Web of Science ®Google Scholar
• Winter N, Lagranderie M, Rauzier J et al. Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene109(1), 47–54 (1991).
   PubMed Web of Science ®Google Scholar
• Winter N, Lagranderie M Gangloff S et al. Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine13(5), 471–478 (1995).
   PubMed Web of Science ®Google Scholar
• Lagranderie M, Murray A Gicquel B et al. Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen. Vaccine11(13), 1283–1290 (1993).
   PubMed Web of Science ®Google Scholar
• Chujoh Y, Matsuo K, Yoshizaki H et al. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B strains by recombinant Mycobacterium bovis BCG-based candidate Vaccine20, 797–804 (2002).
   Web of Science ®Google Scholar
• Kanekiyo M, Matsuo K, Hamatake M et al. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis Bacille Calmette-Guérin expressing human immunodeficiency virus Type 1 gag. J. Virol.79 (14), 8716–8723 (2005).
   PubMed Web of Science ®Google Scholar
• Cayabyab MJ, Hovav AH, Hsu T et al. Generation of CD8 T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1. Env. J. Virol.80(4), 1645–1652 (2006).
   PubMed Web of Science ®Google Scholar
• Yu JS, Peacock JW, Vanleeuwen S et al. Generation of mucosal anti-human immunodeficiency virus Type 1 T cell responses by recombinant Mycobacterium smegmatis. Clin. Vaccine Immunol.30(11), 1204–1211 (2006).
   Google Scholar
• Aravindhan V, Narayanan S, Gautham N et al. Th-2 immunity and CD3+CD45RBlow-activated T cells in mice immunized with recombinant bacillus Calmette-Guerin expressing HIV-1 principal neutralizing determinant epitope. FEMS Immunol. Med. Microbiol.47, 45–55 (2006).
   PubMedGoogle Scholar
• Stover CK, Bansal GP, Hanson MS et al. Protective immunity elicited by recombinant bacille Calmette–Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med.178(1), 197–209 (1993).
   PubMed Web of Science ®Google Scholar
• Langermann S, Palaszynski SR, Burlein JE et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J. Exp. Med.180(6), 2277–2286 (1994).
   PubMed Web of Science ®Google Scholar
• Connell ND, Medina-Acosta E, McMaster WR et al. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl Acad. Sci. USA90(24), 11473–11477 (1993).
   PubMed Web of Science ®Google Scholar
• Varaldo PB, Leite LCC, Dias WO et al. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect. Immun.72(6), 3336–3343 (2004).
   PubMed Web of Science ®Google Scholar
• Pezzat E. Recombinant BCG based HIV development. PhD Thesis. Medicine School. University of Barcelona. June 2005.
   Google Scholar
• Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med.6, 951–955 (2000).
   PubMed Web of Science ®Google Scholar
• Nkolola JP, Wee EGT, Im EJ et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther.11, 1068–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Fennelly GJ, Jacobs WR, Bloom BR. BCG as a recombinant vaccine vector. In: New Generation Vaccines Second Edition. Marcel Dekker, Inc. NY, USA Chapter 28 (1997).
   Google Scholar
• Al Zarouni M, Dale JW. Expression of foreign antigens in Mycobacterium bovis BCG strains using different promoters reveals instability of hsp60 promoter for expression of foreign genes in Mycobacterium bovis BCG strains. Tuberculosis82(6), 283–291 (2002).
   PubMed Web of Science ®Google Scholar
• Falk LA, Goldenthal KL, Esparza J et al. Recombinant Bacillus Calmette-Guérin as a potential vector for preventive HIV Type 1 vaccines. AIDS Res. Hum. Retroviruses16(2), 91–98 (2000).
   PubMedGoogle Scholar
• Wada N, Ohara N, Kameoka M et al. Long-lasting immune response induced by recombinant bacillus Calmette–Guerin (BCG) secretion system. Scand. J. Immunol.43(2), 202–209 (1996).
   PubMed Web of Science ®Google Scholar
• Ami Y, Izumi Y, Matsuo K et al. Priming-boosting vaccination with recombinant Mycobacterium bovis Bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol.79(20), 12871–12879 (2005).
   PubMed Web of Science ®Google Scholar
• McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med.10(11), 1240–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Honda M, Matsuo K, Nakasone T et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette–Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA92(23), 10693–10697 (1995).
   PubMed Web of Science ®Google Scholar
• Lagranderie M, Winter N, Balazuc AM et al. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses.14(18), 1625–1633 (1998).
   PubMed Web of Science ®Google Scholar
• Yasutomi Y, Koenig S, Haun SS et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol.150(7), 3101–3107 (1993).
   PubMed Web of Science ®Google Scholar
• Yasutomi Y, Koenig S, Woods RM et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol.69(4), 2279–2284 (1995).
   PubMed Web of Science ®Google Scholar
• Leung NJ, Aldovini A, Young R, et al. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env and Nef proteins. Virology268(1), 94–103 (2000).
   PubMed Web of Science ®Google Scholar
• Im EJ, Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines3(Suppl. 4), S89–S97 (2004).
   Google Scholar
• Goonetilleke NP, McShane H, Hannan CM et al. Enhanced Immunogenicity and protective efficacy against Mycobacterium Tuberculosis of bacille Calmette–Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol.171, 1602–1609 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiu M, Lagranderie MR, Gicquel BM, Leclerc CD. Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen. Infect. Immun.62(10), 4287–4295 (1994).
   PubMed Web of Science ®Google Scholar
• Kameoka M, Nishino Y, Matsuo K et al. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine12(2), 153–158 (1994).
   PubMed Web of Science ®Google Scholar
• Rubinstein A, Mizrachi Y, Pettoello-Mantovani M et al. Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J. Acquir. Immune Defic. Syndr.22(5), 467–476 (1999).
   PubMed Web of Science ®Google Scholar
• Lallemant-Le Coeur S, Lallemant M, Cheynier D et al. Bacillus Calmette-Guerin immunization in infants born to HIV-1- seropositive mothers. AIDS.5(2), 195–199 (1991).
   PubMed Web of Science ®Google Scholar
• CDC. BCG Vaccination and Pediatric HIV Infection – Rwanda, 1988–1990. MMWR40(48) 833–836 (1991).
   PubMedGoogle Scholar
• Hesseling AC, Schaaf HS, Hanekom WA et al. Danish bacille Calmette-Guérin vaccine-induced disease in Human Immunodeficency virus-infected children. CID371226–1233 (2003).
   PubMed Web of Science ®Google Scholar
• Pezzat E, Virgili G, Etcheverry F et al. Alpha-antigen promoter from M. Tuberculosis and lysine gene complementation prevent the disruption of heterologous HIV-1 gp120 gene expression by genetic rearrangements in BCG strain lysine auxotrophic. A critical issue for rBCG based HIV vaccine. AIDS vaccine 2004 Conference. Lausanne (Switzerland) (Abstract P225) (2004).
   Google Scholar
• Davids V, Hanekom WA, Mansoor N et al. The effect of bacille Calmette–Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants. J. Infect. Dis.193, 531–536 (2006).
   PubMed Web of Science ®Google Scholar
• Gheorghiu M, Lagrange PH, Lagranderie M et al. The effects of dispersed or surface grown cultures, manufacture and control methods on BCG standardization. Dev. Biol. Stand.58(A), 191–205 (1986).
   PubMedGoogle Scholar
• Lagranderie M, Lo-Man R, Deriaud E et al. Genetic control af antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen Infect. Immun.65(8), 3057–3064 (1997).
   PubMed Web of Science ®Google Scholar
• Lim EM, Lagranderie M, LeGrand R et al. Recombinant Mycobacterium bovis BCG producing the N-terminal half of SIVmac251 env antigen induces neutralizing antibodies and cytotoxic T lymphocyte responses in mice and guinea pigs. AIDS Res. Hum. Retroviruses13(18), 1573–1581 (1997).
   PubMed Web of Science ®Google Scholar
• Hiroi T, Goto H, Someya K et al. HIV Mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. J. Immunol.167, 5862–5867 (2001).
   PubMed Web of Science ®Google Scholar
• Kawahara M, Hashimoto A, Toida I, Honda M. Oral recombinant Mycobacterium bovis bacillus Calmette–Guérin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin. Immunol.105(3), 326–331 (2002).
   PubMed Web of Science ®Google Scholar
• Kawahara M, Matsuo K, Nakasone T et al. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette–Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen Vaccine21, 158–166 (2002).
   PubMed Web of Science ®Google Scholar
• Kawahara M, Matsuo K and Honda M. Intradermal and oral immunization with recombinant Mycobacterium bovis BCG expressing the simian immunodeficiency virus Gag protein induces long-lasting, antigen-specific immune responses in guinea pigs Clin. Immunol.119, 67–78 (2006).
   PubMed Web of Science ®Google Scholar
• Someya K, Cecilia D, Ami Y. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette–Guerin Env V3 elicits neutralizing antibody-mediated protection against simian–human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol.79(3), 1452–1462 (2005).
   PubMed Web of Science ®Google Scholar
• Mederle I, Le Grand R, Vaslin B et al. Mucosal administration of three recombinant Mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine21, 4153–4166 (2003).
   PubMed Web of Science ®Google Scholar